CLMR number: CLMR (23)A/01
Date issued: 12th January 2023
The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a company-led medicines recall for: Fluphenazin-neuraxpharm® D 25 & 100 mg/ml Solution for Injection (Mawdsley-Brooks & Company Limited).
Fluphenazin-neuraxpharm® D 100 mg/ml Solution for Injection [unlicensed medicine]
Batch number
Expiry Date
Pack Size
First Distributed
200686
01/2024
5 x 1ml
21/05/2021
Active ingredient: Fluphenazine
Fluphenazin-neuraxpharm® D 25 mg/ml Solution for Injection [unlicensed medicine]
Batch number
Expiry Date
Pack Size
First Distributed
202052
01/2024
5 x 1ml
16/07/2021
Active ingredient: Fluphenazine
Specific batches of product are recalled as a precautionary measure due to validation tests demonstrating the leaching of filter additives that are above the acceptable limit.
This recall is being issued as a company-led medicines recall as the products are only supplied to limited number of customers, and the manufacturer has full traceability of the product’s distribution.
Remaining stock of the above batches should be quarantined and returned to Mawdsleys directly.
Company Contact for medical information enquiries
For medical information enquiries, please contact Michelle Biggs at michelle.biggs@mawdsleys.co.uk
Company Contact for stock enquiries
For stock information enquiries, please contact Andrea Dunlop at andrea.dunlop@mawdsleys.co.uk
To view the alert please visit the GOV.UK website.
The post Company led medicines recall: Fluphenazin-neuraxpharm® D 25 & 100 mg/ml Solution for Injection Mawdsley-Brooks & Company Limited appeared first on PSNC Website.